Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week

Mona Fiuzat, Carine E. Hamo, Javed Butler, William T. Abraham, Ersilia M. DeFilippis, Gregg C. Fonarow, Joann Lindenfeld, Robert J. Mentz, Mitchell A. Psotka, Scott D. Solomon, John R. Teerlink, Muthiah Vaduganathan, Orly Vardeny, John J.V. McMurray, Christopher M. O'Connor

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.

Original languageEnglish
Pages (from-to)504-510
Number of pages7
JournalJournal of the American College of Cardiology
Volume79
Issue number5
DOIs
StatePublished - 8 Feb 2022

Keywords

  • FDA
  • HFrEF
  • clinical trials
  • device therapy
  • drug therapy
  • guideline directed medical therapy
  • heart failure
  • medical therapy
  • medication

Fingerprint

Dive into the research topics of 'Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week'. Together they form a unique fingerprint.

Cite this